The Primary Breast Cancer Therapy Group (NSABP) was established in 1958 and now has 104 affiliated institutions, 21 of which are granted. The membership consists of 328 surgical, 244 medical and 127 radiation oncologists. There are also 140 pathologists, immunologists and endocrinologists. The Operations Office and Biostatistical Center employs 61 persons in positions ranging from data clerks to physicians and statisticians. Contributing members are supported by 238 nurses and data collectors. The NSABP objectives are: (a) to assess the worth of new and promising therapies when employed either alone or in concert with other modalities for the treatment of such tumors, (b) to allow for evaluation of the worth of modalities presently employed in the treatment of such cancers when used in innovative ways to test current biological hypotheses, (c) to gather biological and other pertinent data so as to better understand the natural history of patients with such tumors and to permit formulation of better strategies for their treatment, (d) to permit formulation of interventions that could enhance the quality of life of breast cancer patients, and (e) to improve the quality of care of breast cancer patients through the process of educating physicians to the findings and experiences of this group. Since August, 1971, eleven protocols have been implemented to evaluate therapy in Stages I and II breast cancer. As of December, 1981, 7689 eligible patients meeting common protocol requirements have been accrued; 6184 (80%) were alive and being followed with 1600 actively receiving therapy. During 1981 those patients generated approximately 60,000 forms and materials requiring processing by the Biostatistical Center. The present application is submitted so that efforts toward fulfilling the above documented objectives may be continued.
The specific aims are to: (1) complete patient accrual in Protocol Nos. B-06, 11, 12, 13 and 14, (b) continue follow-up in all protocols, (3) design and implement successor protocols, (4) design and perform special studies relating to biological considerations associated with NSABP protocols, (5) extend quality control procedures, (6) perform data analyses, and (7) develop and implement methodological investigations associated with cross-protocol comparisons.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA012027-15
Application #
3556032
Study Section
(SRC)
Project Start
1976-12-01
Project End
1987-03-31
Budget Start
1986-02-01
Budget End
1987-03-31
Support Year
15
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Saha, Poornima; Regan, Meredith M; Pagani, Olivia et al. (2017) Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol 35:3113-3122
Regan, M M; Walley, B A; Francis, P A et al. (2017) Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 28:2225-2232
Ternès, Nils; Rotolo, Federico; Michiels, Stefan (2017) Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials. BMC Med Res Methodol 17:83
Ribi, Karin; Bernhard, Jürg; Luo, Weixiu et al. (2016) Reply to F. Tomao et al. J Clin Oncol 34:4189-4190
Regan, Meredith M; Francis, Prudence A; Pagani, Olivia et al. (2016) Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol 34:2221-31
Cheung, Winson Y; Renfro, Lindsay A; Kerr, David et al. (2016) Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. J Clin Oncol 34:1182-9
Phillips, Kelly-Anne; Regan, Meredith M; Ribi, Karin et al. (2016) Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer 114:956-64
Christian, Nicholas J; Ha, Il Do; Jeong, Jong-Hyeon (2016) Hierarchical likelihood inference on clustered competing risks data. Stat Med 35:251-67
Ribi, Karin; Luo, Weixiu; Bernhard, Jürg et al. (2016) Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol 34:1601-10
Johansson, Harriet; Gray, Kathryn P; Pagani, Olivia et al. (2016) Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Res 18:110

Showing the most recent 10 out of 264 publications